摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Nα-Benzoyllysine | 116783-33-6

中文名称
——
中文别名
——
英文名称
Nα-Benzoyllysine
英文别名
N-benzoyllysine;Nα-Benzoyl-DL-lysin;α-Benzoyl-lysin;N2-benzoyl-lysine;Inakt. ε-Amino-α-benzamino-n-capronsaeure;N2-benzoyl-DL-lysine;N2-Benzoyl-DL-lysin;N2-Benzoyl-lysin;6-azaniumyl-2-benzamidohexanoate
N<sup>α</sup>-Benzoyllysine化学式
CAS
116783-33-6
化学式
C13H18N2O3
mdl
——
分子量
250.298
InChiKey
IYHOIXNPULYXFO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    211 °C
  • 沸点:
    518.1±45.0 °C(Predicted)
  • 密度:
    1.186±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.3
  • 重原子数:
    18
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    92.4
  • 氢给体数:
    3
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • TREATING BLADDER TUMOR CELLS USING FIBRONECTIN ATTACHMENT PROTEIN AS A TARGET
    申请人:Purdue Research Foundation
    公开号:US20170095568A1
    公开(公告)日:2017-04-06
    Composition and methods are disclosed for utilizing microaggregation of FAP-containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum-free conditions such as the ones found in the lumen of the bladder.
    揭示了利用FAP含有复合物的微聚集来促进其快速内吞的组合物和方法。这种方法允许将细胞毒性货物与FAP抗体或FAP脂质体复合物耦合,被肿瘤膀胱细胞摄取。重要的是,这种方法即使在无血清条件下,如在膀胱腔内发现的条件下,也是高效的。
  • Compositions for the delivery of antigens
    申请人:Emisphere Technologies, Inc.
    公开号:US20020001591A1
    公开(公告)日:2002-01-03
    The present invention relates to compositions and methods for orally delivering antigens. The antigen and an adjuvant are combined with an acylated amino acid or polyamino acid and, a sulfonated amino acids or polyamino acid, or a salt of the foregoing.
    本发明涉及用于口服给药抗原的组合物和方法。将抗原和佐剂与酰化氨基酸或多氨基酸,磺化氨基酸或多氨基酸,或其盐结合。
  • Composition containing a penem or carbapenem antibiotic
    申请人:SANKYO COMPANY LIMITED
    公开号:EP0178911A2
    公开(公告)日:1986-04-23
    57 Administration of an N-acylated amino acid (ornithine, lysine, phenylglycine or phenylalanine) in association with a penem or carbapenem antibiotic relieves or eliminates the renal problems associated with administration of the antibiotic alone. The amino acid and antibiotic may be formulated together as a composition or administered separately, either simultaneously or sequentially. A pharmaceutical composition may be prepared simply by mixing the two components.
    57 将 N-酰化氨基酸鸟氨酸、赖酸、苯甘酸或苯丙酸)与培南类或碳青霉烯类抗生素联合给药,可缓解或消除与单独给药抗生素相关的肾脏问题。 氨基酸和抗生素可一起配制成组合物,也可同时或依次单独给药。 只需将两种成分混合即可制备成药物组合物。
  • METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE
    申请人:TOKUYAMA CORPORATION
    公开号:EP1338588A1
    公开(公告)日:2003-08-27
    Provided is a separating method for an optical isomer mixture comprising the steps of mixing an amino acid derivative such as N-(tert-butoxycarbonyl)-DL-alanine in which optical isomers of a D type and an L type are present in a mixture with a hydrophilic compound such as β-cyclodextrin having a different affinity to two kinds of the optical isomers described above and then bringing the resulting aqueous solution or aqueous suspension into contact with a hydrophobic substance such as a solid matter subjected on a surface thereof to hydrophobic treatment on the condition that the pH is 3.5 or lower or under the coexistence of ions including an atomic group having hydrophobicity which can be a counter ion for the amino acid derivative described above such as a triethylammonium ion to thereby separate the D type amino acid derivative from the L type amino acid derivative present in the above aqueous solution or aqueous suspension.
    本发明提供了一种光学异构体混合物的分离方法,该方法包括以下步骤:将氨基酸生物(如 N-(叔丁氧羰基)-DL-丙氨酸)与亲性化合物(如对上述两种光学异构体具有不同亲和力的 β-环糊精)混合,在混合物中存在 D 型和 L 型光学异构体。对上述两种光学异构体具有不同亲和力的环糊精的混合物,然后将所得溶液或悬浮液与疏性物质接触,如在其表面进行疏处理的固体物质,条件是 pH 值为 3.5或更低的pH值,或在包括具有疏性的原子团的离子共存的条件下,该原子团可以是上述氨基酸生物的反离子,例如三乙基离子,从而将上述溶液或悬浮液中的D型氨基酸生物与L型氨基酸生物分离。
  • METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE
    申请人:Ajinomoto Co., Inc.
    公开号:EP3375883A1
    公开(公告)日:2018-09-19
    The present invention provides a method for producing Nε-dodecanoyl-L-lysine using an enzyme having properties suitable for the industrial production of Nε-dodecanoyl-L-lysine. More specifically, the present invention provides a method for producing Nε-acyl-L-lysine including reacting a carboxylic acid or a salt thereof and L-lysine or a salt thereof in the presence of any of the following (A) to (C) proteins to produce Nε-acyl-L-lysine: (A) a protein comprising an amino acid sequence of SEQ ID NO: 1; (B) a protein comprising an amino acid sequence in which one or several amino acid residues are inserted, added, deleted, or substituted in the amino acid sequence of SEQ ID NO: 1 and having Nε-acyl-L-lysine-specific aminoacylase activity; and (C) a protein comprising an amino acid sequence having 90% or higher homology with the amino acid sequence of SEQ ID NO: 1 and having Nε-acyl-L-lysine-specific aminoacylase activity.
    本发明提供了一种利用一种酶生产 Nε-十二碳酰基-L-赖氨酸的方法,该酶具有适于工业生产 Nε-十二碳酰基-L-赖氨酸的特性。更具体地说,本发明提供了一种生产 Nε-酰基-L-赖氨酸的方法,包括在下列(A)至(C)任一蛋白质存在下,使羧酸或其盐和 L-赖氨酸或其盐反应,以生产 Nε-酰基-L-赖氨酸: (A) 包含 SEQ ID NO: 1 氨基酸序列的蛋白质; (B) 包含在 SEQ ID NO: 1 的氨基酸序列中插入、添加、删除或替换了一个或多个氨基酸残基的氨基酸序列并具有 Nε-酰基-L-赖氨酸特异性基酰化酶活性的蛋白质;以及 (C) 包含与 SEQ ID NO: 1 的氨基酸序列具有 90% 或更高同源性且具有 Nε-酰基-L-赖氨酸特异性 基化酶活性的氨基酸序列的蛋白质。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫